Using a natural compound to improve insulin sensitivity in type 2 diabetes
Targeting galectin-3 to overcome insulin resistance in type 2 diabetes
This study is looking at a new treatment for type 2 diabetes that targets a protein called galectin-3, using a natural compound called TFD100, to help improve insulin resistance and potentially offer a new option for managing the condition.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Glycomantra, INC. NIH-funded |
| Lab location | 1 site (Halethorpe, United States) |
| Project ID | NIH-10916440 on NIH RePORTER |
What this research studies
This research focuses on addressing insulin resistance, a major issue in type 2 diabetes, by targeting a protein called galectin-3. The team has developed a potent antagonist of galectin-3, known as TFD100, which is derived from a natural dietary source. The goal is to complete preclinical studies that will support an application to the FDA for a first-in-human clinical trial. If successful, this could lead to a new treatment option that directly affects insulin receptor signaling.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with type 2 diabetes, particularly those experiencing insulin resistance.
Not a fit: Patients who do not have type 2 diabetes or those whose diabetes is not related to insulin resistance may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel treatment for patients with type 2 diabetes, potentially improving their insulin sensitivity and glucose control.
How similar studies have performed: While targeting galectin-3 is a novel approach, similar strategies in addressing insulin resistance have shown promise in preliminary studies.
Where this research is happening
Halethorpe, United States
- Glycomantra, INC. — Halethorpe, United States (Active)
Researchers
- Principal investigator: Ahmed, Hafiz — Glycomantra, INC.
- Study coordinator: Ahmed, Hafiz
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.